ReviewFrontiers in immunology2025
mRNA vaccines transform personalized lung cancer treatment.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress of machine learning applications in gastric cancer diagnosis and therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Targeting the Gut-Brain-Ferroptosis Axis: Molecular Mechanisms and Therapeutic Potential in Alzheimer's Disease and Epilepsy.Journal of molecular neuroscience : MN · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted therapy and immunotherapy represent major innovations in the treatment of lung cancer. However, in patients with driver gene-positive tumors, the emergence of acquired resistance to targeted drugs is inevitable. As for immunotherapy, its efficacy in early-stage lung cancer patients remains uncertain due to strong immune heterogeneity. In advanced and locally advanced patients, high tumor mutational burden leads to significant genomic instability and tumor progression, and resistance still inevitably develops even with standard chemotherapy combined with immunotherapy. Cancer vaccines, as an approach that activates the antitumor immune cycle from its origin, offer advantages such as the ability to target multiple antigens, minimal off-target effects, a wide therapeutic window, and low toxicity. Furthermore, such vaccines can induce long-lasting immune memory and possess a certain capacity to remodel the tumor immune microenvironment, which helps prevent cancer recurrence, demonstrating broad prospects in lung cancer treatment. Currently, various types of tumor vaccines (including those based on microorganisms, peptides, proteins, exosomes, and DNA) have been developed, yet they often face limitations in safety, insufficient personalization, and immature production pipelines. In contrast, messenger RNA (mRNA)-based vaccines offer distinct advantages, including the efficient generation of protective immune responses, relatively low side effects, and lower acquisition costs, making them a forefront option for novel lung cancer therapies. This review summarizes the current research status of lung cancer vaccines, clarifies the unique therapeutic advantages of mRNA vaccines compared to traditional vaccine modalities, and highlights existing challenges associated with mRNA vaccines. It also provides an overview of current clinical trials of mRNA vaccines for lung cancer and proposes rational design and clinical application strategies for personalized mRNA vaccines within the framework of precision oncology, based on evidence-based medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.